Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A bilateral, chronic, diffuse granulomatous panuveitis typically characterized by serous retinal detachment and frequently associated with neurological (meningitis), auditory, and dermatological alterations.
Biomarker and diagnostic research for Vogt-Koyanagi-Harada disease has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
1 clinical trial registered, 1 recruiting. Interventions under study include drug therapy. Research is primarily sponsored by academic and government institutions.
238 publications have been identified in PubMed for Vogt-Koyanagi-Harada disease. Research spans Review / Meta-Analysis (29%), Case Report / Case Series (23%), and Epidemiology / Natural History (15%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 68 | 29% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 6:47 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Vogt-Koyanagi-Harada disease
Patient case studies |
53 |
23% |
Disease patterns and progression | 35 | 15% |
Clinical study results | 27 | 12% |
Laboratory research | 27 | 12% |
Testing and diagnosis research | 18 | 8% |
Other research | 5 | 2% |
New treatment approaches | 1 | 0% |
Alshalan HA (2026). [PMID: 41835311](https://pubmed.ncbi.nlm.nih.gov/41835311/). *Case Rep Ophthalmol*. [Case Report / Case Series]
Luo H (2026). [PMID: 41924279](https://pubmed.ncbi.nlm.nih.gov/41924279/). *Front Immunol*. [Clinical Trial Publication]
Gentile P (2026). [PMID: 41636860](https://pubmed.ncbi.nlm.nih.gov/41636860/). *Int Ophthalmol*. [Epidemiology / Natural History]
Bleicher ID (2026). [PMID: 42080125](https://pubmed.ncbi.nlm.nih.gov/42080125/). *J Vitreoretin Dis*. [Case Report / Case Series]
Oshiro A (2026). [PMID: 41533903](https://pubmed.ncbi.nlm.nih.gov/41533903/). *Invest Ophthalmol Vis Sci*. [Diagnostic / Biomarker]
Cho YC (2026). [PMID: 41883730](https://pubmed.ncbi.nlm.nih.gov/41883730/). *Ophthalmol Sci*. [Diagnostic / Biomarker]
Huang Y (2026). [PMID: 41640516](https://pubmed.ncbi.nlm.nih.gov/41640516/). *Front Med (Lausanne)*. [Case Report / Case Series]
Belletti M (2026). [PMID: 41417717](https://pubmed.ncbi.nlm.nih.gov/41417717/). *Ocular immunology and inflammation*. [Clinical Trial Publication]
Amir MM (2026). [PMID: 41894300](https://pubmed.ncbi.nlm.nih.gov/41894300/). *Medicine (Baltimore)*. [Case Report / Case Series]
Liba T (2026). [PMID: 41238446](https://pubmed.ncbi.nlm.nih.gov/41238446/). *Ocul Immunol Inflamm*. [Review / Meta-Analysis]
AI-curated news mentioning Vogt-Koyanagi-Harada disease
Updated Sep 8, 2026
A recent case report details a patient with Vogt-Koyanagi-Harada disease experiencing progressive visual loss and multisystem involvement. This case highlights the complexities of diagnosing and managing this rare autoimmune condition.
A recent case report highlights a rare instance of immune checkpoint inhibitor-induced Vogt-Koyanagi-Harada-like disease, complicated by inflammatory macular neovascularization. This study contributes to the understanding of adverse effects associated with immune therapies.